DEFA14A: Denali Capital Secures $20M PIPE for Semnur Merger

Denali Capital Acquisition Corp. has secured a $20 million private investment in public equity (PIPE) financing from JW Capital Securities Limited to support its merger with Semnur Pharmaceuticals, Inc.

Summary

• Denali Capital Acquisition Corp. (Denali) entered into a Securities Purchase Agreement with Semnur Pharmaceuticals, Inc. (Semnur) and a Purchaser (JW Capital Securities Limited) on August 20, 2025.
• The agreement facilitates a Private Investment in Public Equity (PIPE) financing of $20,000,000.
• The Purchaser has agreed to buy 1,250,000 shares of common stock of the combined company (New Semnur) at a price of $16.00 per share.
• This PIPE financing is contingent upon the consummation of the Business Combination between Denali and Semnur, which is expected to close immediately following the merger.
• Semnur will cause 12,000,000 shares of New Semnur common stock, beneficially owned by its parent company Scilex Holding Company, to be deposited into an escrow account no later than 20 business days after the Business Combination's closing.
• The Business Combination is based on an Agreement and Plan of Merger dated August 30, 2024, which was amended on April 16, 2025, and July 22, 2025.
• The PIPE Shares will be issued under an exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D, with the Purchaser confirming accredited investor status and investment intent.

Sentiment

Score: 7

Explanation: The sentiment is positive as the filing announces a significant capital raise and the continued progression of a strategic merger, indicating forward momentum for the company. While risks are acknowledged, the primary focus is on the successful execution of a planned transaction.

Positives

• Secured $20,000,000 in PIPE financing, providing additional capital for the combined entity, New Semnur.
• The Business Combination with Semnur Pharmaceuticals is progressing, with the SEC declaring the Form S-4 registration statement effective.
• The PIPE financing demonstrates investor confidence in the planned merger and the future prospects of New Semnur.

Risks

• General economic, political, and business conditions could adversely affect the Business Combination.
• There is a risk of the parties being unable to consummate the Business Combination or the Merger Agreement being terminated.
• The outcome of any legal proceedings that may be instituted against the parties following the announcement of the Business Combination could be unfavorable.
• The possibility of receiving an unsolicited offer from another party for an alternative business transaction could interfere with the Business Combination.
• Failure to obtain the necessary approvals from stockholders of Semnur or shareholders of Denali could prevent the transaction.
• The anticipated benefits of the Business Combination may not be realized, potentially due to delays or difficulties in integrating the businesses.
• The Business Combination could disrupt current plans and operations of both Denali and Semnur.
• The combined company's ability to grow, manage growth profitably, and retain key employees is subject to risks.
• The amount of redemption requests made by Denali's shareholders could impact the capital available to the combined company.
• There is a risk of inability to obtain or maintain the listing of the post-acquisition company's securities on Nasdaq or OTC Markets.
• Costs related to the Business Combination could be higher than anticipated.

Future Outlook

The filing indicates an expectation for the successful consummation of the Business Combination between Denali and Semnur, leading to future opportunities for the combined company (New Semnur). The closing of the PIPE financing is anticipated to occur immediately following the Business Combination.

Management Comments

• Lei Huang, Chief Executive Officer of Denali Capital Acquisition Corp., signed the Current Report on Form 8-K and the Securities Purchase Agreement, indicating management's commitment to the transaction.
• Jaisim Shah, Chief Executive Officer of Semnur Pharmaceuticals, Inc., signed the Securities Purchase Agreement, signifying Semnur's commitment to the PIPE financing and the Business Combination.

Industry Context

This announcement reflects a common trend in the financial markets where Special Purpose Acquisition Companies (SPACs) like Denali merge with private operating companies, such as Semnur Pharmaceuticals, to take them public. The accompanying PIPE financing is a standard mechanism to provide additional capital and validate the valuation of the combined entity, particularly in the pharmaceutical and biotechnology sectors which often require significant capital for development and commercialization.

Related Party Transactions

• Semnur will cause 12,000,000 shares of New Semnur common stock beneficially owned by its parent company, Scilex Holding Company, to be deposited into an escrow account following the Business Combination.

Stakeholder Impact

• Shareholders of Denali Capital Acquisition Corp. will vote on the Business Combination and will become shareholders of New Semnur upon completion.
• Semnur Pharmaceuticals, Inc. will become a wholly-owned subsidiary of Denali (New Semnur), impacting its existing shareholders and management.
• JW Capital Securities Limited, as the Purchaser in the PIPE financing, will become a significant new investor in New Semnur.
• Scilex Holding Company, as Semnur's parent, will have a portion of its New Semnur shares placed in escrow, affecting its liquidity and control over those shares.

Next Steps

• Consummation of the Business Combination between Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc.
• Closing of the $20,000,000 PIPE financing immediately following the Business Combination.
• Deposit of 12,000,000 shares of New Semnur common stock into an escrow account by Semnur's parent company, Scilex Holding Company, within 20 business days following the Business Combination's closing.
• Shareholders of Denali Capital Acquisition Corp. will hold an extraordinary general meeting to approve the Business Combination and related matters.

Key Dates

Recommendation

The filing provides a positive update on a strategic transaction, including a significant capital raise and the progression of a merger. This indicates a clear path forward for the company. However, without detailed financial performance metrics or a comprehensive business plan for the combined entity, a stronger 'buy' recommendation is not warranted. Existing shareholders should 'hold' to see the successful completion of the merger and subsequent operational and financial disclosures of New Semnur, while new investors would benefit from more comprehensive financial data before making a definitive investment decision.

Keywords

SPAC, Merger, PIPE Financing, Semnur Pharmaceuticals, Denali Capital Acquisition Corp., Business Combination, Private Equity, Biotechnology, SEC Filing, Scilex Holding Company